Kura Oncology, Inc.
Healthcare · Biotechnology · $818M market cap · Ranked #785 of 1,207
Sits near the middle of the universe on the composite score. Ranks in the 35th percentile overall.
Figures come straight from the company’s filed quarterly report and feed the six-factor model (growth, quality, and value especially). This is a summary of what was reported — research, not a recommendation, and there are no analyst estimates behind it, so it isn’t a beat-or-miss call.
The latest raw values feeding the six factors.
Every rating we’ve ever assigned KURA — append-only and hash-verified. We don’t revise or delete past calls.
9 rating changes across 103 snapshots — each with the factor shift that drove it.
The full append-only record of every call we’ve made on KURA— the accountability history mainstream sites quietly edit and we can’t — is part of Proofstock Plus.
Unlock with Plus